Core Viewpoint - Hims & Hers Health, Inc. is facing a class action securities lawsuit due to alleged securities fraud that occurred between April 29, 2025, and June 23, 2025 [1][2] Group 1: Allegations and Impact - The lawsuit claims that Hims engaged in deceptive promotion and selling of illegitimate versions of Wegovy®, which jeopardized patient safety [2] - It is alleged that this situation posed a significant risk of termination of the Company's collaboration with Novo Nordisk [2] - The defendants' positive statements regarding the Company's business and prospects are claimed to be materially misleading and lacking a reasonable basis [2] Group 2: Legal Process and Participation - Investors who suffered losses during the specified timeframe have until August 25, 2025, to request appointment as lead plaintiff [3] - Class members may be entitled to compensation without any out-of-pocket costs or fees [3] Group 3: Legal Firm Background - Levi & Korsinsky has a history of securing hundreds of millions of dollars for shareholders and has extensive expertise in complex securities litigation [4] - The firm has been recognized in ISS Securities Class Action Services' Top 50 Report for seven consecutive years as one of the leading securities litigation firms in the U.S. [4]

Core Viewpoint - Rosen Law Firm is reminding investors who purchased common stock of Hims & Hers Health, Inc. during the specified Class Period of the upcoming lead plaintiff deadline for a class action lawsuit [1][2] Group 1: Class Action Details - The Class Period for the lawsuit is from April 29, 2025, to June 23, 2025, and the lead plaintiff deadline is August 25, 2025 [1] - Investors who purchased Hims common stock during the Class Period may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [1] Group 2: Legal Representation - Investors are encouraged to select qualified legal counsel with a proven track record in securities class actions, as many firms may not have the necessary experience or resources [3] - Rosen Law Firm has a history of successful settlements, including the largest securities class action settlement against a Chinese company at the time, and has recovered hundreds of millions for investors [3] Group 3: Case Allegations - The lawsuit alleges that Hims & Hers made false and misleading statements regarding its partnership with Novo Nordisk A/S, which affected investor decisions [4] - Specific claims include the failure to disclose the nature of the collaboration with Novo, the approval of Hims' compounded semaglutide products, and the availability of branded Wegovy alongside these products [4]

Core Viewpoint - A lawsuit has been filed against Hims & Hers Health, Inc. and its senior executives for potential violations of federal securities laws, following allegations of misrepresentation regarding a partnership with Novo Nordisk [1][2][4]. Group 1: Lawsuit Details - Investors have until August 25, 2025, to request to lead the case, which is pending in the U.S. District Court for the Northern District of California [2]. - The lawsuit claims violations under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 on behalf of investors who purchased Hims & Hers securities [2]. Group 2: Company Operations - Hims & Hers operates a telehealth platform providing online consultations, prescription medications, and wellness products [3]. - The company announced a collaboration with Novo Nordisk on April 29, 2025, to sell the weight loss drug Wegovy on its platform [3]. Group 3: Allegations of Misrepresentation - Hims & Hers allegedly misrepresented the nature of its partnership with Novo Nordisk, claiming it could offer both Wegovy and compounded semaglutide, and that its sales complied with FDA regulations [4]. Group 4: Stock Market Reaction - Following Novo Nordisk's announcement on June 23, 2025, that it was terminating the partnership due to Hims & Hers' deceptive practices, the stock price fell by $22.24, or over 34%, from $64.22 to $41.98 per share [5].

SAN DIEGO, July 14, 2025 (GLOBE NEWSWIRE) -- Robbins Geller Rudman & Dowd LLP announces that purchasers or acquirers of Hims & Hers Health, Inc. (NYSE: HIMS) securities between April 29, 2025 and June 23, 2025, both dates inclusive (the "Class Period"), have until Monday, August 25, 2025 to seek appointment as lead plaintiff of the Hims & Hers class action lawsuit. Captioned Sookdeo v. Hims & Hers Health, Inc., No. 25-cv-05315 (N.D. Cal.), the Hims & Hers class action lawsuit charges Hims & Hers as well as ...

Core Viewpoint - A lawsuit has been filed against Hims & Hers Health, Inc. and its senior executives for potential violations of federal securities laws, following allegations of misrepresentation regarding a partnership with Novo Nordisk [1][2][4]. Group 1: Lawsuit Details - Investors have until August 25, 2025, to request to lead the case, which is pending in the U.S. District Court for the Northern District of California [2]. - The lawsuit asserts claims under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 on behalf of investors who purchased Hims & Hers securities [2]. Group 2: Company Operations - Hims & Hers operates a telehealth platform providing online consultations, prescription medications, and wellness products [3]. - The company announced a collaboration with Novo Nordisk on April 29, 2025, to sell the weight loss drug Wegovy on its platform [3]. Group 3: Allegations of Misrepresentation - Hims & Hers allegedly misrepresented the nature of its partnership with Novo Nordisk, claiming it could offer both Wegovy and compounded semaglutide to customers [4]. - The company also purportedly stated that its sale of compounded semaglutide complied with FDA regulations [4]. Group 4: Stock Market Reaction - Following Novo Nordisk's announcement on June 23, 2025, that it was terminating the partnership due to Hims & Hers' deceptive practices, the stock price fell by $22.24 per share, a decline of over 34%, from $64.22 to $41.98 [5].

Core Viewpoint - Hims & Hers Health, Inc. is facing a class action securities lawsuit due to alleged securities fraud that occurred between April 29, 2025, and June 23, 2025 [1][2] Group 1: Lawsuit Details - The lawsuit claims that Hims was involved in the deceptive promotion and sale of illegitimate versions of Wegovy®, which posed risks to patient safety [2] - It is alleged that this situation created a substantial risk of termination of the Company's collaboration with Novo Nordisk [2] - The defendants' positive statements regarding the Company's business and prospects are claimed to be materially misleading and lacking a reasonable basis [2] Group 2: Next Steps for Investors - Investors who suffered losses during the specified timeframe have until August 25, 2025, to request appointment as lead plaintiff [3] - Participation in the lawsuit does not require serving as a lead plaintiff, and class members may be entitled to compensation without any out-of-pocket costs [3] Group 3: Firm Background - Levi & Korsinsky has a history of securing hundreds of millions of dollars for shareholders and has extensive experience in complex securities litigation [4] - The firm has been recognized in ISS Securities Class Action Services' Top 50 Report for seven consecutive years as one of the leading securities litigation firms in the U.S. [4]

Core Viewpoint - Hims & Hers Health, Inc. is facing a class action securities lawsuit due to alleged securities fraud that occurred between April 29, 2025, and June 23, 2025 [1][2] Group 1: Allegations and Impact - The lawsuit claims that Hims was involved in the deceptive promotion and sale of illegitimate versions of Wegovy®, which jeopardized patient safety [2] - It is alleged that this situation posed a significant risk of termination of the Company's collaboration with Novo Nordisk [2] - The defendants' positive statements regarding the Company's business and prospects are claimed to be materially misleading and lacking a reasonable basis [2] Group 2: Legal Process and Participation - Investors who suffered losses during the specified timeframe have until August 25, 2025, to request appointment as lead plaintiff [3] - Participation in the lawsuit does not require serving as a lead plaintiff, and class members may be entitled to compensation without any out-of-pocket costs [3] Group 3: Firm Background - Levi & Korsinsky, LLP has a history of securing hundreds of millions of dollars for shareholders and is recognized as one of the top securities litigation firms in the United States [4]

Core Points - Rosen Law Firm is reminding purchasers of Hims & Hers Health, Inc. common stock of the lead plaintiff deadline for a class action lawsuit, which is August 25, 2025 [1] - Investors who purchased Hims common stock during the specified class period may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [1][2] Company Details - The lawsuit alleges that Hims made false and misleading statements regarding its partnership with Novo Nordisk A/S, particularly about the availability of the weight-loss drug Wegovy for Hims subscribers [4] - Specific claims include that Hims failed to disclose the nature of its collaboration with Novo, which would ensure continued access to Wegovy, and that positive statements were made about the partnership while omitting critical details [4] Legal Representation - Investors are encouraged to select qualified legal counsel with a proven track record in securities class actions, as many firms may not have the necessary experience or resources [3] - Rosen Law Firm has a history of successful settlements in securities class actions, including a record settlement against a Chinese company and significant recoveries for investors [3]

Core Viewpoint - Hims & Hers Health, Inc. is facing a class action lawsuit due to allegations of misleading statements and deceptive practices related to the promotion of illegitimate products, which may jeopardize its collaboration with Novo Nordisk [3]. Summary by Relevant Sections Allegations - The complaint claims that during the class period from April 29, 2025, to June 23, 2025, Hims engaged in deceptive promotion and selling of illegitimate versions of Wegovy®, risking patient safety [3]. - It is alleged that this conduct poses a substantial risk of termination of the company's collaboration with Novo Nordisk [3]. - The positive statements made by the defendants regarding the company's business and prospects are claimed to be materially misleading and lacking a reasonable basis [3]. Class Action Details - Shareholders who purchased HIMS shares during the specified class period are encouraged to register for the class action, with a deadline set for August 25, 2025 [4]. - Registration allows shareholders to be enrolled in a portfolio monitoring system for updates on the case [4]. - There is no cost or obligation for shareholders to participate in the case [4]. Law Firm Information - The Gross Law Firm is a nationally recognized class action law firm dedicated to protecting investors' rights against deceit and fraud [5]. - The firm aims to ensure companies adhere to responsible business practices and seeks recovery for investors who suffered losses due to misleading statements [5].

Core Viewpoint - Hims & Hers Health Inc. is under investigation for potential securities fraud following the termination of its partnership with Novo Nordisk due to allegations of deceptive marketing and selling unapproved products [2][3] Group 1: Company Actions and Allegations - Hims & Hers is accused of making materially false or misleading statements regarding its GLP-1 offerings and the partnership with Novo Nordisk during the class period from April 29, 2025, to June 22, 2025 [3] - The termination of the partnership with Novo Nordisk led to a significant decline in Hims & Hers' stock price, dropping over 34% in intraday trading, indicating investor concerns about regulatory compliance and reputational risks [2] Group 2: Legal Proceedings - Berger Montague is investigating potential securities fraud claims against Hims & Hers, with a deadline for investors to seek lead plaintiff status by August 25, 2025 [1] - The investigation focuses on whether Hims & Hers and certain executives violated federal securities laws by providing false or misleading information to investors [3]